The potential therapy is the first to emerge from CRISPR’s and Vertex’s strategic partnership, which was expanded in 2021.
Affecting more than 20 million people worldwide, SCD is a group of inherited red blood cell disorders which cause red blood cells to become hard and sticky and appear in a c-shaped form known as ‘sickle’.
The lifelong illness can lead to serious health problems, including strokes, eye problems, infections and episodes of pain.
